SCHEMBL8963513

SCHEMBL8963513

COC(=O)c1c[nH]c(-c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
HTT P42858 1/20 0.49
ALDH1A1 P00352 1/20 0.48
NR4A2 P43354 1/20 0.48
EGFR P00533 1/20 0.48
AXL P30530 2/20 0.47
NEK1 Q96PY6 1/20 0.47
SGK1 O00141 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GAA P10253 1/20 0.45
CDC7 O00311 1/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1156503 0.83 SMN1; SMN2 (0.54) TSHRHTTALDH1A1GAARAB9A
SCHEMBL23320060 0.80 KMO (0.52) TSHREGFRGAACDC7RAB9A
SCHEMBL25352091 0.80 LMNA (0.59) TSHRHTTALDH1A1GAAMAPT
SCHEMBL10938050 0.80 CDC7 (0.37) HTTALDH1A1NR4A2AXLNEK1
SCHEMBL27878777 0.80 TSHR (0.68) TSHRHTTALDH1A1NR4A2EGFR
SCHEMBL3635974 0.80 HTT (0.52) TSHRHTTALDH1A1NR4A2EGFR
SCHEMBL1156402 0.80 NR4A2 (0.46) TSHRHTTALDH1A1NR4A2AXL
SCHEMBL29815918 0.78 NPC1 (0.49) TSHRHTTALDH1A1RAB9AMAPT
SCHEMBL194193 0.78 NPC1 (0.49) TSHRHTTALDH1A1RAB9AMAPT
SCHEMBL731835 0.78 TSHR (0.50) TSHREGFRGAARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112823151-B Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2024-11-15 CN disclosed
WO-2024009283-A1 AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-01-11 WO disclosed
WO-2024009283-A1 AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-01-11 WO disclosed
US-20210236466-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2021-08-05 US disclosed
US-20210236466-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2021-08-05 US disclosed
CN-112823151-A Compounds and compositions for treating diseases associated with STING activity 艾福姆德尤股份有限公司 2021-05-18 CN disclosed
EP-3818044-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2021-05-12 EP disclosed
US-5543286-A CONTAINING AN ORGANIC SILVER SALT AND A PYRROLE COMPOUND;HIGH CONTRAST IMAGES CANON KABUSHIKI KAISHA (JP) 1996-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210236466-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 TSHR 4487/4885HTT 2427/4885ALDH1A1 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.